Fever; A spontaneous report was received from a consumer concerning a 76-year old male patient who received Moderna's COVID-19 vaccine (mRNA-1273) and developed fever (pyrexia).  The patient's medical history was not reported. Concomitant products included chemotherapy.  On 25 Feb 2021, the patient received their second of two planned doses of mRNA-1273 (Lot number: 002A21A) intramuscularly for prophylaxis of COVID-19 infection.   On 26 Feb 2021, next day of receiving vaccine, the patient developed fever and was taken to the emergency room and subsequently admitted on 02 Mar 21 for the fever. Treatment for the event included were antibiotics.  The patient received both scheduled doses of mRNA-1273 prior to the events; therefore, action taken with the drug in response to the event is not applicable.  The outcome of event, fever was considered as unknown.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the event, a causal relationship cannot be excluded.